HR Execs on the Move

Zero Gravity Solutions

www.zerogsi.com

 
Zero Gravity Solutions is an agricultural biotechnology public company commercializing its technology derived from and designed for Space with significant applications on Earth. These technologies are focused on providing valuable solutions to challenges facing world agriculture. ZGSI’s two primary categories of technologies aimed at sustainable agriculture are: 1) BAM-FX™ technology, a cost effective, ionic micronutrient delivery system for plants currently being introduced commercially into world agriculture by Zero Gravity’s wholly owned subsidiary BAM Agricultural Solutions and 2) Directed Selection™, utilized in the development and production, in the prolonged zero/micro gravity environment of the International Space Station, of large volumes of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zerogsi.com
  • 190 NW Spanish River Blvd.
    Boca Raton, FL USA 33431
  • Phone: 561.416.0400

Executives

Name Title Contact Details

Similar Companies

emcresearch

emcresearch is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma Connections Worldwide

Pharma Connections Worldwide is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMarker Strategies

BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).